PL1760153T3 - Hybrydowy wektor adenowirusowy/alfawirusowy do skutecznego podawania i ekspresji genów terapeutycznych w komórkach nowotworowych - Google Patents

Hybrydowy wektor adenowirusowy/alfawirusowy do skutecznego podawania i ekspresji genów terapeutycznych w komórkach nowotworowych

Info

Publication number
PL1760153T3
PL1760153T3 PL05750184T PL05750184T PL1760153T3 PL 1760153 T3 PL1760153 T3 PL 1760153T3 PL 05750184 T PL05750184 T PL 05750184T PL 05750184 T PL05750184 T PL 05750184T PL 1760153 T3 PL1760153 T3 PL 1760153T3
Authority
PL
Poland
Prior art keywords
sequence
hybrid vector
adenoviral
adenovirus
expression
Prior art date
Application number
PL05750184T
Other languages
English (en)
Inventor
Cheng Qian
Min Guan
Picazo Cristian Smerdou
Valtueña Jesus Prieto
Original Assignee
Proyecto De Biomedicina Cima S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto De Biomedicina Cima S L filed Critical Proyecto De Biomedicina Cima S L
Publication of PL1760153T3 publication Critical patent/PL1760153T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05750184T 2004-05-20 2005-05-18 Hybrydowy wektor adenowirusowy/alfawirusowy do skutecznego podawania i ekspresji genów terapeutycznych w komórkach nowotworowych PL1760153T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200401219A ES2292271B1 (es) 2004-05-20 2004-05-20 Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
EP05750184A EP1760153B1 (en) 2004-05-20 2005-05-18 Adenovirus/alphavirus hybrid vector for the effective administration and expression of therapeutic genes in tumour cells
PCT/ES2005/000277 WO2005112541A2 (es) 2004-05-20 2005-05-18 Un vector híbrido adenovirus-alfavirus para la administración eficaz y expresión de genes terapéuticos en células tumorales

Publications (1)

Publication Number Publication Date
PL1760153T3 true PL1760153T3 (pl) 2011-04-29

Family

ID=35428710

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05750184T PL1760153T3 (pl) 2004-05-20 2005-05-18 Hybrydowy wektor adenowirusowy/alfawirusowy do skutecznego podawania i ekspresji genów terapeutycznych w komórkach nowotworowych

Country Status (20)

Country Link
US (1) US7850957B2 (pl)
EP (1) EP1760153B1 (pl)
JP (1) JP4767945B2 (pl)
CN (1) CN100580085C (pl)
AT (1) ATE488596T1 (pl)
AU (2) AU2005244625A1 (pl)
BR (1) BRPI0510905A (pl)
CA (1) CA2567455A1 (pl)
CY (1) CY1111496T1 (pl)
DE (1) DE602005024805D1 (pl)
DK (1) DK1760153T3 (pl)
ES (2) ES2292271B1 (pl)
HR (1) HRP20110059T1 (pl)
MX (1) MXPA06013277A (pl)
PL (1) PL1760153T3 (pl)
PT (1) PT1760153E (pl)
RS (1) RS51559B (pl)
RU (1) RU2394104C2 (pl)
SI (1) SI1760153T1 (pl)
WO (1) WO2005112541A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100361710C (zh) * 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
EP1900749A1 (en) * 2006-09-12 2008-03-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells
HRP20100638T2 (hr) * 2006-11-28 2011-03-31 Proyecto De Biomedicina Cima Viralni vektori i njihova uporaba
KR20130010121A (ko) 2010-03-23 2013-01-25 인트렉손 코포레이션 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
CN101966341B (zh) * 2010-09-30 2012-06-27 中国农业科学院哈尔滨兽医研究所 腺病毒/甲病毒复制子嵌合载体猪瘟疫苗及其应用
KR20140027063A (ko) * 2010-10-28 2014-03-06 버지니아 커먼웰스 유니버시티 치료와 병용하는 암 영상화: 치료진단
FI3536797T3 (fi) * 2013-02-01 2023-03-23 Selexis Sa Siirtogeenin tehostettu ilmentäminen ja prosessointi
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
EP2878674A1 (en) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stable episomes based on non-integrative lentiviral vectors
CN106367401A (zh) * 2016-08-29 2017-02-01 黄朝述 具有基因协同元件的病毒及其应用
KR102056066B1 (ko) * 2016-12-09 2019-12-17 진메디신 주식회사 세포외 기질 분해 인자를 발현하는 재조합 아데노바이러스를 포함하는 항암용 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US5144482A (en) 1991-05-13 1992-09-01 Gould Dennis R Three dimensional viewing apparatus including a stack of transparent plates and related method
WO1995016772A1 (en) * 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
SE9401091D0 (sv) * 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5985846A (en) 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
EP0954579A1 (en) * 1996-06-20 1999-11-10 Merck & Co., Inc. Gene therapy for obesity
EP0932693A1 (en) * 1996-10-10 1999-08-04 Henrik Garoff Alphavirus-retrovirus vectors
US6333030B1 (en) * 1996-11-19 2001-12-25 Uab Research Foundation Chimeric retrovirus/adenovirus system
AU6962698A (en) * 1997-04-11 1998-11-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Transgenomic viruses and the use thereof
CA2309826A1 (en) * 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
ES2268797T3 (es) * 1997-11-14 2007-03-16 Sanofi Pasteur Limited Vectores alvirus.
NZ505325A (en) * 1997-12-23 2003-07-25 Crucell Holland B Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
JP2002517234A (ja) * 1998-06-09 2002-06-18 メルク・アンド・カンパニー・インコーポレーテッド 遺伝子治療用の新規アデノウイルスベクター
GB9817660D0 (en) * 1998-08-13 1998-10-07 Angeletti P Ist Richerche Bio Adenoviral vectors encoding erythropoietin and their use in gene therapy
US6375944B1 (en) * 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
CA2360796A1 (en) * 1999-02-04 2000-08-10 Merck & Co., Inc. Improved helper dependent vector system for gene therapy
WO2000073424A1 (en) * 1999-05-28 2000-12-07 Mount Sinai School Of Medicine A novel baculovirus/adenovirus hybrid vector for the rescue, production and titration of high-capacity adenovirus amplicon vectors
EP1318839A2 (en) * 2000-03-24 2003-06-18 Cell Genesys, Inc. Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
DE10056210A1 (de) * 2000-11-13 2002-05-29 Arimedes Biotechnology Gmbh Virales Expressionssystem
WO2002064097A2 (en) * 2001-02-12 2002-08-22 The Penn State Research Foundation Vegf-d expression in brain cancer
WO2002079447A2 (en) * 2001-03-30 2002-10-10 Avigenics, Inc. Avian lysozyme promoter
US7238346B2 (en) * 2002-07-08 2007-07-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw High capacity recombinant adenoviral vector for treatment of hemophilia A

Also Published As

Publication number Publication date
RS51559B (sr) 2011-06-30
CA2567455A1 (en) 2005-12-01
RU2394104C2 (ru) 2010-07-10
JP2007537742A (ja) 2007-12-27
EP1760153A2 (en) 2007-03-07
SI1760153T1 (sl) 2011-02-28
AU2005244625A1 (en) 2005-12-01
AU2010214637B2 (en) 2012-04-26
PT1760153E (pt) 2010-12-23
ES2292271A1 (es) 2008-03-01
US20070224170A1 (en) 2007-09-27
AU2010214637A1 (en) 2010-09-16
ES2292271B1 (es) 2009-02-16
DE602005024805D1 (de) 2010-12-30
EP1760153B1 (en) 2010-11-17
CY1111496T1 (el) 2015-08-05
MXPA06013277A (es) 2007-02-28
JP4767945B2 (ja) 2011-09-07
WO2005112541A2 (es) 2005-12-01
BRPI0510905A (pt) 2007-11-06
ES2356322T3 (es) 2011-04-06
DK1760153T3 (da) 2011-02-21
CN1957086A (zh) 2007-05-02
WO2005112541A3 (es) 2006-03-23
RU2006145306A (ru) 2008-06-27
CN100580085C (zh) 2010-01-13
ATE488596T1 (de) 2010-12-15
US7850957B2 (en) 2010-12-14
HRP20110059T1 (hr) 2011-03-31

Similar Documents

Publication Publication Date Title
JP7546925B2 (ja) 核酸とｃａｒ修飾免疫細胞とを含む治療薬およびその使用
CN103614416B (zh) 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途
AU672195B2 (en) Defective recombinant adenoviruses expressing cytokines for use in antitumoral treatment
CA2477954A1 (en) Means and methods for the production of adenovirus vectors
JP2023524976A5 (pl)
SI1760153T1 (sl) Adenovirusni/alfavirusni hibridni vektor za uäśinkovito uporabo in ekspresijo terapevtskih genov v tumorskih celicah
CA2229631A1 (en) Gene therapy using ovine adenoviral vectors
RU2006146665A (ru) Конструирование рекомбинанта онколитического аденовируса, специфически экспрессирующего иммуномодуляторный фактор gm-csf в опухолевых клетках и его применение
WO2003023000A3 (en) Linear dna fragments for gene expression
JP2026063215A5 (pl)
CA2378586A1 (en) Replication-competent anti-cancer vectors
RU2006105195A (ru) Синтетический ген, кодирующий человеческий антиген эпидермального фактора роста 2/neu, и его применение
CN107058231A (zh) 携带融合蛋白基因的重组腺病毒及其制备方法和应用
JP2007504840A5 (pl)
CN116836283B (zh) 具有多种免疫调节因子的增强型溶瘤病毒及其制备方法和应用
JP2009535031A5 (pl)
RU2507265C2 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pCI-UB-POLYEPI, СОДЕРЖАЩАЯ ЭПИТОПЫ ОПУХОЛЬ-АССОЦИИРОВАННЫХ АНТИГЕНОВ ДЛЯ КОЛОРЕКТАЛЬНОГО РАКА, И СПОСОБ ЕЕ ПРИМЕНЕНИЯ ДЛЯ СТИМУЛЯЦИИ СПЕЦИФИЧЕСКОГО ПРОТИВООПУХОЛЕВОГО ИММУННОГО ОТВЕТА ПРОТИВ КЛЕТОК КОЛОРЕКТАЛЬНОГО РАКА
CA3106093C (en) ANTI-TUMOR COMPOSITION
Guo et al. Adenovirus co-expressing CD40 ligand and interleukin (IL)-2 contributes to maturation of dendritic cells and production of IL-12
CN117083390A (zh) 用于治疗癌症的腺病毒
Tagawa et al. Cancer therapy with local oncolysis and topical cytokine secretion
CN120738154B (zh) 一种低免疫原性的AsCas12a蛋白突变体及其应用
CN111500632A (zh) 表达st13和trail的溶瘤腺病毒构建及其应用
CN119932112A (zh) 一种携载双重免疫激活配体的溶瘤腺病毒kd02载体、制备方法及应用
ES3035814T3 (en) Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof